News|Articles|November 17, 2026

Nerandomilast Benefit in Autoimmune ILD Consistent by Time Since Diagnosis

Fact checked by: Alex Hillenbrand

A FIBRONEER-ILD subgroup analysis presented at ACR 2026 found no heterogeneity in nerandomilast's effect on FVC decline or clinical events.

Nerandomilast efficacy by time since ILD diagnosis

The effect of nerandomilast on slowing lung function decline in patients with autoimmune interstitial lung disease (ILD) and progressive pulmonary fibrosis (PPF) was consistent regardless of time since ILD diagnosis, according to a subgroup analysis of the phase 3 FIBRONEER-ILD trial presented at ACR Convergence 2026 in Orlando, Florida.1 No evidence of heterogeneity was found for forced vital capacity (FVC) change at week 52 or for time to first acute exacerbation, respiratory hospitalization, or death.1

Nerandomilast is a preferential phosphodiesterase 4B (PDE4B) inhibitor with immunomodulatory, vascular, and antifibrotic effects.1 FIBRONEER-ILD previously met its primary end point of reduced FVC decline in PPF, with numerical benefits on clinically relevant outcomes including survival.1 Madelon Vonk, MD, PhD, of Radboud University Medical Center in Nijmegen, the Netherlands, and colleagues assessed whether time since ILD diagnosis modified these effects in the autoimmune ILD population.1

"In the FIBRONEER-ILD trial in patients with PPF, the effect of nerandomilast on slowing ILD progression in patients with autoimmune ILD was consistent across subgroups by time since diagnosis of ILD," Vonk and colleagues wrote.1

Autoimmune ILD population in FIBRONEER-ILD

Patients with PPF were randomized 1:1:1 to nerandomilast 9 mg twice daily, nerandomilast 18 mg twice daily, or placebo.1 Of 325 patients with autoimmune ILD, the most common underlying diagnoses were rheumatoid arthritis (n = 118; 36.3%) and systemic sclerosis (n = 75; 23.1%).1 At baseline, 34.2% were receiving nintedanib and 55.1% were receiving immunosuppressants, and mean exposure to trial medication was 15.8 months.1

Key Takeaways

What is nerandomilast?

Nerandomilast is an oral preferential PDE4B inhibitor with immunomodulatory, vascular, and antifibrotic effects, evaluated in the phase 3 FIBRONEER-ILD trial in progressive pulmonary fibrosis.

Did time since ILD diagnosis affect nerandomilast response?

No. Among 325 patients with autoimmune ILD, interaction tests showed no heterogeneity in the effect on FVC at week 52 or on time to exacerbation, respiratory hospitalization, or death.

Which autoimmune diseases were most represented?

Rheumatoid arthritis accounted for 36.3% and systemic sclerosis for 23.1% of patients with autoimmune ILD in the analysis.

Time since ILD diagnosis was one year or less in 56 patients (17.2%), more than one to three years in 87 (26.8%), more than three to five years in 67 (20.6%), and more than five years in 115 (35.4%).1

FVC and clinical outcomes across subgroups

FVC change from baseline at week 52 showed no consistent pattern across time-since-diagnosis subgroups in any treatment group.1 The treatment effect of nerandomilast vs placebo showed no evidence of heterogeneity by subgroup (interaction P = .98 for 9 mg twice daily; P = .40 for 18 mg twice daily).1

Time to first acute exacerbation of ILD, respiratory hospitalization, or death over the whole trial also showed no statistical evidence of heterogeneity (interaction P = .33 for 9 mg twice daily; P = .18 for 18 mg twice daily).1 The safety and tolerability profile was generally similar across subgroups.1

The abstract text did not report per-arm sample sizes, adjusted FVC differences in mL, or adverse event rates by subgroup.1 Three of the nine authors are employees of Boehringer Ingelheim, which developed nerandomilast.1 Earlier FIBRONEER-ILD analyses reported nerandomilast slowed FVC decline in the overall autoimmune ILD subgroup and trended toward benefit in myositis-associated ILD.2,3

References
  1. Vonk M, Bruni C, Bernstein E, et al. Efficacy and safety of nerandomilast in patients with autoimmune interstitial lung disease (ILD) and progressive pulmonary fibrosis in subgroups by time since ILD diagnosis. Abstract 1617. Presented at: ACR Convergence 2026; November 6-11, 2026; Orlando, FL. https://acrabstracts.org/abstract/efficacy-and-safety-of-nerandomilast-in-patients-with-autoimmune-interstitial-lung-disease-ild-and-progressive-pulmonary-fibrosis-in-subgroups-by-time-since-ild-diagnosis/
  2. Rheumatology Live. Nerandomilast slows lung function decline, reduces mortality risk in autoimmune ILD subgroup. Published June 10, 2026. Accessed November 16, 2026. https://www.rheum-live.com/view/nerandomilast-lung-function-mortality-autoimmune-ild-subgroup
  3. Rheumatology Live. Nerandomilast trends toward benefit in myositis-associated ILD subgroup. Published November 10, 2026. Accessed November 16, 2026. https://www.rheum-live.com/view/nerandomilast-trends-toward-benefit-myositis-associated-ild-subgroup

Related to this article